Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors

Authors

Mark H. O'Hara, University of Pennsylvania
Wells Messersmith, University of Colorado
Hedy Kindler, The University of Chicago Medicine
Wei Zhang, Eli Lilly and Company
Celine Pitou, Eli Lilly and Company
Anna M. Szpurka, Eli Lilly and Company
Dan Wang, Eli Lilly and Company
Sheng-Bin Peng, Eli Lilly and Company
Burkhard Vangerow, Eli Lilly and Company
Anis A. Khan, AstraZeneca
Mythili Koneru, Eli Lilly and Company
Andrea Wang-Gillam, Washington University School of Medicine in St. Louis

Journal

Journal of Pancreatic Cancer

Publication Date

2020

Volume

6

Issue

1

First Page

21

Last Page

31

Document Type

Open Access Publication

DOI

10.1089/pancan.2019.0018

Rights and Permissions

This is a copy of an article published in the Journal of Pancreatic Cancer © 2020 © Mary Ann Liebert, Inc.; Journal of Pancreatic Cancer is available online at: http://online.liebertpub.com.

Recommended Citation

O'Hara, Mark H.; Messersmith, Wells; Kindler, Hedy; Zhang, Wei; Pitou, Celine; Szpurka, Anna M.; Wang, Dan; Peng, Sheng-Bin; Vangerow, Burkhard; Khan, Anis A.; Koneru, Mythili; and Wang-Gillam, Andrea, "Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors." Journal of Pancreatic Cancer. 6, 1. 21 - 31. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9722